Latest News
About Tonix Pharmaceuticals
Tonix is a biotechnology company where scientific breakthroughs begin with respecting the patients’ lived experiences. Our pipeline responds to the call for solutions to complex, chronic and sometimes invisible conditions with scientific rigor, integrity, and purpose. We are dedicated to developing therapies for conditions that defy easy answers, including nociplastic pain, immunology / immuno-oncology, and infectious diseases. We aim to develop impactful treatments that make patients feel seen and heard, reducing the limitations these conditions impose, enabling people to expect more, and be energized by possibility.
At Tonix, we listen, we develop, we deliver – so that patients feel seen, heard, and empowered to live fully again.
Therapeutic Areas
Immunology and Immuno-oncology
We are advancing scientific programs that focus on therapeutics to prevent organ transplant rejection, to manage autoimmune conditions, and to improve responses to immunotherapy in certain cancers.*
Central Nervous System
Tonix is dedicated to finding cures for difficult to treat, widely occurring, chronic disorders of the central nervous system including pain, neurological, psychiatric and addiction conditions.* Our goal is to heal sufferings of millions through scientific advancements.
Infectious Disease
Tonix’s infectious disease portfolio targets pathogenic infections, including monkeypox and smallpox for biodefense. Through its live virus vaccine platform and in-house capabilities, Tonix strives to be prepared for future pandemics.
Rare Disease
Tonix is committed to improving patient care, including for those suffering from rare diseases, often for which no drug has been approved. Rare diseases are often caused by genetic disorders and are characterized by complex symptoms. A rare disease is a condition that affects fewer than 200,000 people in the US as defined in the Orphan Drug Act of 1983.
Key Clinical & Preclinical Programs
We are advancing innovative programs across multiple therapeutic areas.
Preclinical
Phase I
Phase II
Phase III
TNX-102 SL Acute Stress Disorder/Acute Stress Reaction
Investor-Initiated Study
Phase 2 topline data planned 2H’26.
Phase 2
TNX-1500 Prevention of Organ Transplant Rejection
Investigator-Initiated Study
Phase 2 Study Planned Mid-26
Phase 2
TNX-2900 Prader-Willi Syndrome
FDA Orphan Drug and Rare Pediatric Disease Designation
Phase 2 Planned for 1Q 2027
Phase 2 Ready
TNX-1700 Gastric and Colorectal Cancer
Preclinical
Preclinical
TNX-801 Prevention of Mpox or Smallpox
Preclinical
Preclinical
TNX-4200 CD45
Preclinical
Preclinical